Evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera.
Ranawaka A P M PereraRonald KoOwen T Y TsangDavid S C HuiMike Y M KwanChristopher J BrackmanEsther M W ToHui Ling YenKathy LeungSamuel M S ChengKin Ho ChanKarl C K ChanKa-Chi LiLinda Jean SaifVanessa R BarrsJoseph T WuThomas H C SitLeo L M PoonJoseph S Malik PeirisPublished in: Journal of clinical microbiology (2021)
Surrogate neutralization assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that can be done without biosafety level 3 containment and in multiple species are desirable. We evaluate a recently developed surrogate virus neutralization test (sVNT) in comparison to 90% plaque reduction neutralization tests (PRNT90) in human, canine, cat, and hamster sera. With PRNT90 as the reference, sVNT had sensitivity of 98.9% and specificity of 98.8%. Using a panel of immune sera corresponding to other coronaviruses, we confirm the lack of cross-reactivity to other coronaviruses in SARS-CoV-2 sVNT and PRNT90, except for cross-reactivity to SARS-CoV-1 in sVNT.